These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31689975)

  • 1. Effect of Lactose Pseudopolymorphic Transition on the Aerosolization Performance of Drug/Carrier Mixtures.
    Della Bella A; Müller M; Danani A; Soldati L; Bettini R
    Pharmaceutics; 2019 Nov; 11(11):. PubMed ID: 31689975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of lactose pseudopolymorphic form on salbutamol sulfate-lactose interactions in DPI formulations.
    Traini D; Young PM; Thielmann F; Acharya M
    Drug Dev Ind Pharm; 2008 Sep; 34(9):992-1001. PubMed ID: 18800259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-spraying of carriers (mannitol-lactose) as a method to improve aerosolization performance of salbutamol sulfate dry powder inhaler.
    Ferdynand MS; Nokhodchi A
    Drug Deliv Transl Res; 2020 Oct; 10(5):1418-1427. PubMed ID: 31933129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mannitol Polymorphs as Carrier in DPIs Formulations: Isolation Characterization and Performance.
    Altay Benetti A; Bianchera A; Buttini F; Bertocchi L; Bettini R
    Pharmaceutics; 2021 Jul; 13(8):. PubMed ID: 34452073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agglomerated novel spray-dried lactose-leucine tailored as a carrier to enhance the aerosolization performance of salbutamol sulfate from DPI formulations.
    Molina C; Kaialy W; Chen Q; Commandeur D; Nokhodchi A
    Drug Deliv Transl Res; 2018 Dec; 8(6):1769-1780. PubMed ID: 29260462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved aerosolization performance of salbutamol sulfate formulated with lactose crystallized from binary mixtures of ethanol-acetone.
    Kaialy W; Ticehurst MD; Murphy J; Nokhodchi A
    J Pharm Sci; 2011 Jul; 100(7):2665-84. PubMed ID: 21268026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation into alternative sugars as potential carriers for dry powder formulation of budesonide.
    Momin MN; Hedayati A; Nokhodchi A
    Bioimpacts; 2011; 1(2):105-11. PubMed ID: 23678414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation.
    Zeng XM; Martin GP; Tee SK; Ghoush AA; Marriott C
    Int J Pharm; 1999 May; 182(2):133-44. PubMed ID: 10341303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols.
    Zeng XM; Pandhal KH; Martin GP
    Int J Pharm; 2000 Mar; 197(1-2):41-52. PubMed ID: 10704792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Powder flow analysis: A simple method to indicate the ideal amount of lactose fines in dry powder inhaler formulations.
    Hertel M; Schwarz E; Kobler M; Hauptstein S; Steckel H; Scherließ R
    Int J Pharm; 2018 Jan; 535(1-2):59-67. PubMed ID: 29100914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of carrier particle shape on dry powder inhaler performance.
    Kaialy W; Alhalaweh A; Velaga SP; Nokhodchi A
    Int J Pharm; 2011 Dec; 421(1):12-23. PubMed ID: 21945739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carrier-based dry powder inhalation: Impact of carrier modification on capsule filling processability and in vitro aerodynamic performance.
    Faulhammer E; Wahl V; Zellnitz S; Khinast JG; Paudel A
    Int J Pharm; 2015 Aug; 491(1-2):231-42. PubMed ID: 26136200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lactose as a carrier in dry powder formulations: the influence of surface characteristics on drug delivery.
    Zeng XM; Martin GP; Marriott C; Pritchard J
    J Pharm Sci; 2001 Sep; 90(9):1424-34. PubMed ID: 11745794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of carrier size and morphology on the dispersion of salbutamol sulphate after aerosolization at different flow rates.
    Zeng XM; Martin GP; Marriott C; Pritchard J
    J Pharm Pharmacol; 2000 Oct; 52(10):1211-21. PubMed ID: 11092565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Granulated Lactose as a Carrier for Dry Powder Inhaler Formulations 2: Effect of Drugs and Drug Loading.
    Du P; Du J; Smyth HDC
    J Pharm Sci; 2017 Jan; 106(1):366-376. PubMed ID: 27939234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-lactose binding aspects in adhesive mixtures: controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces.
    Zhou QT; Morton DA
    Adv Drug Deliv Rev; 2012 Mar; 64(3):275-84. PubMed ID: 21782866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate.
    Tee SK; Marriott C; Zeng XM; Martin GP
    Int J Pharm; 2000 Nov; 208(1-2):111-23. PubMed ID: 11064216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extrinsic lactose fines improve dry powder inhaler formulation performance of a cohesive batch of budesonide via agglomerate formation and consequential co-deposition.
    Kinnunen H; Hebbink G; Peters H; Huck D; Makein L; Price R
    Int J Pharm; 2015 Jan; 478(1):53-59. PubMed ID: 25448567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterizing the Surface Roughness Length Scales of Lactose Carrier Particles in Dry Powder Inhalers.
    Tan BMJ; Chan LW; Heng PWS
    Mol Pharm; 2018 Apr; 15(4):1635-1642. PubMed ID: 29490144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.